DE60021113D1 - Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können - Google Patents

Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können

Info

Publication number
DE60021113D1
DE60021113D1 DE60021113T DE60021113T DE60021113D1 DE 60021113 D1 DE60021113 D1 DE 60021113D1 DE 60021113 T DE60021113 T DE 60021113T DE 60021113 T DE60021113 T DE 60021113T DE 60021113 D1 DE60021113 D1 DE 60021113D1
Authority
DE
Germany
Prior art keywords
albumin
glycosylative
illnesses
treating
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60021113T
Other languages
English (en)
Other versions
DE60021113T2 (de
Inventor
Margo Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLYCADIA, INC., PHILADELPHIA, PA., US
Original Assignee
Exocell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exocell Inc filed Critical Exocell Inc
Application granted granted Critical
Publication of DE60021113D1 publication Critical patent/DE60021113D1/de
Publication of DE60021113T2 publication Critical patent/DE60021113T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
DE60021113T 1999-07-08 2000-07-06 Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können Expired - Lifetime DE60021113T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US349853 1999-07-08
US09/349,853 US6355680B1 (en) 1996-02-20 1999-07-08 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
PCT/US2000/018449 WO2001003684A2 (en) 1999-07-08 2000-07-06 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies

Publications (2)

Publication Number Publication Date
DE60021113D1 true DE60021113D1 (de) 2005-08-04
DE60021113T2 DE60021113T2 (de) 2006-06-01

Family

ID=23374238

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60021113T Expired - Lifetime DE60021113T2 (de) 1999-07-08 2000-07-06 Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können

Country Status (9)

Country Link
US (2) US6355680B1 (de)
EP (1) EP1242069B1 (de)
JP (1) JP4833468B2 (de)
KR (2) KR20020033725A (de)
AT (1) ATE298568T1 (de)
AU (1) AU5915100A (de)
CA (1) CA2378456C (de)
DE (1) DE60021113T2 (de)
WO (1) WO2001003684A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922830D0 (en) * 1999-09-27 1999-11-24 Novartis Ag Processes
GB0002740D0 (en) * 2000-02-07 2000-03-29 Novartis Ag Organic compounds
ATE448194T1 (de) * 2000-08-29 2009-11-15 Biocon Ltd Verwendung einer pharmazeutischen zusammensetzung mit einem para-aminophenylessigsäurederivat für die behandlung von entzündlichen erkrankungen des magen-darmtrakts
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
JP2006501161A (ja) 2002-06-11 2006-01-12 ニトロメッド インク． ニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物ならびに使用方法
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
US7932366B2 (en) * 2004-07-07 2011-04-26 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
AR061623A1 (es) * 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
US20080255236A1 (en) * 2007-04-12 2008-10-16 Glycadia, Inc. Methods and Composition Comprising 2-[(3-Chlorophenyl)Amino] Phenylacetic Acid for Alzheimer's Disease
WO2009037707A2 (en) * 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20100035993A1 (en) * 2008-08-06 2010-02-11 Cohen Margo P Methods and compositions comprising 2-[(3-chlorophenyl) amino] phenylacetic acid for hyperpermeability and neovascularization disorders of the retina
WO2011090943A1 (en) * 2010-01-22 2011-07-28 Baylor College Of Medicine Removal of pathological albumin from a subject's plasma
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
EP4083029A1 (de) * 2013-08-20 2022-11-02 University of Washington through its Center for Commercialization Neuartige und spezifische inhibitoren von cytochrom-p450-26-retinsäure-hydroxylase
US20170157010A1 (en) * 2015-12-08 2017-06-08 Glycadia, Inc. Methods and compositions for treatment of disorders associated with damage induced by free radicals
CN109694330B (zh) * 2017-10-24 2023-10-20 乳源瑶族自治县东阳光生物科技有限公司 一种酸的制备方法
CN107793323A (zh) * 2017-11-23 2018-03-13 华中科技大学 一种双氯芬酸甲酯的合成方法
CN108047072A (zh) * 2017-11-23 2018-05-18 深圳华中科技大学研究院 一种双氯芬酸钠的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133740C (de) * 1965-04-08
US3558690A (en) * 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
DK125461B (da) * 1967-12-20 1973-02-26 Ciba Geigy Ag Fremgangsmåde til fremstilling af substituerede phenyleddikesyrer eller salte deraf.
US3652762A (en) * 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
DK143104C (da) * 1970-09-09 1981-11-09 Ciba Geigy Ag Analogifremgangsmaade til fremstilling af anilinophenylacetamidderivater eller salte deraf
JPS5259131A (en) * 1975-11-10 1977-05-16 Daito Koeki Production of substituted phenyl acetic acids and salts
JPS5283425A (en) * 1975-12-30 1977-07-12 Daito Koeki Production of substituted anilinophenyl acetic acid
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
JPS5920256A (ja) * 1982-07-27 1984-02-01 Hokuriku Seiyaku Co Ltd ２−（２，６−ジフルオロアニリノ）フエニル酢酸誘導体
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
US5021576A (en) * 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
IT1256345B (it) * 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
US5518720A (en) * 1992-12-30 1996-05-21 Exocell, Inc. Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
WO1997029746A1 (en) * 1996-02-20 1997-08-21 Exocell, Inc. Inhibition of protein glycation and prevention of vasculopathy
US5994401A (en) * 1996-02-20 1999-11-30 Exocell, Inc. In Vivo Methods to reduce hypercholesterolemia and improve vascular dysfunction
JP2003119142A (ja) * 1997-03-31 2003-04-23 Mitsubishi Pharma Corp 糖化蛋白変性物質生成阻害剤

Also Published As

Publication number Publication date
JP4833468B2 (ja) 2011-12-07
DE60021113T2 (de) 2006-06-01
AU5915100A (en) 2001-01-30
US20010034359A1 (en) 2001-10-25
EP1242069A2 (de) 2002-09-25
WO2001003684A2 (en) 2001-01-18
WO2001003684A3 (en) 2002-06-06
KR100817443B1 (ko) 2008-03-27
KR20020033725A (ko) 2002-05-07
ATE298568T1 (de) 2005-07-15
US6552077B2 (en) 2003-04-22
US6355680B1 (en) 2002-03-12
KR20070104478A (ko) 2007-10-25
JP2003504328A (ja) 2003-02-04
CA2378456C (en) 2012-04-10
CA2378456A1 (en) 2001-01-18
EP1242069B1 (de) 2005-06-29

Similar Documents

Publication Publication Date Title
DE60021113D1 (de) Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE60204322D1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
AP1498A (en) Inhibitors of impdh enzyme.
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
MXPA04001037A (es) Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina.
NO20006645D0 (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
ATE301995T1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
DE69934595D1 (de) Verwendung von verbindungen die alpha2-antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
ATE298573T1 (de) Triazinonverbindungen zur behandlung von durch den befall mit parasitischen protozoen bedingten krankheiten
DE60119514D1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentansäure
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
BR0112123A (pt) Composto

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GLYCADIA, INC., PHILADELPHIA, PA., US

8364 No opposition during term of opposition